Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
about
Involvement of caspase 8 and c-FLIPL in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expressionDifferential cleavage of Mst1 by caspase-7/-3 is responsible for TRAIL-induced activation of the MAPK superfamilyIrradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosisThe anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID miceApoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategiesClinical perspectives of TRAIL: insights into central nervous system disordersAntioxidants of Edible MushroomsMolecular targets of TRAIL-sensitizing agents in colorectal cancerThe Janus Face of Death Receptor Signaling during Tumor ImmunoeditingTrailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsSalicylate-induced degeneration of cochlea spiral ganglion neurons-apoptosis signalingA novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous routeWhat was old is new again: using the host response to diagnose infectious disease.Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin).Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.PPARĪ³ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy fluxEngineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cellsNeural stem cell therapy for cancer.Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.Novel Structurally Related Flavones Augment Cell Death Induced by rhsTRAILVitamin D Modulation of TRAIL Expression in Human Milk and Mammary Epithelial Cells.Apoptosis of multiple myeloma.DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas.5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cellsDifferential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.Analysis of death receptor 5 and caspase-8 expression in primary and metastatic head and neck squamous cell carcinoma and their prognostic impactmTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cellsPredominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.Mig-2 attenuates cisplatin-induced apoptosis of human glioma cells in vitro through AKT/JNK and AKT/p38 signaling pathwaysDysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesc-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance.Fasting enhances TRAIL-mediated liver natural killer cell activity via HSP70 upregulationEvaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomasRapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt.
P2860
Q24321282-28FF9B59-BC5C-44A6-95A4-83C9B39E3AD1Q24642376-CA9B3CEE-EFEB-46A6-AF71-34EBB4F1BE08Q24654366-DA865289-8561-4AF4-A5EB-73005E8A470EQ24798681-993C7AAB-AC31-4018-9093-4043A0C5F6AFQ24811656-0F294931-9B0A-4338-896B-D139ED037BE7Q26750639-001A0D7C-ACC0-4C00-B0C1-D0615A1DC8E3Q26766570-DF72980D-0784-4B00-842A-FBF81E53DE5FQ26777836-3DB9736C-4C81-430E-9338-11D89E57F5E2Q26822382-EF23AB54-A0DC-49F8-AEDD-6E742DF05E29Q28070036-A54A3C92-629A-46B0-BAAC-20EA6B74C23CQ28391040-09E12EE6-30F4-4A93-A23C-DE24E3982BDCQ28395683-62B1A371-FEF5-4BD7-A830-8CB97C5A3E76Q28817910-11D6C261-E999-47BB-B795-716E20534533Q30376327-5F37B114-50FF-4E94-8A88-43604991EFA5Q30576902-A9B551EC-F17E-43E5-ACF7-FCDA7868E91AQ31120918-76E460B0-D659-469E-9B28-4A675BEED619Q33213461-76756137-A888-4D30-A583-580381205AE2Q33515420-FF382706-CB51-4DE0-A7D5-872225F6658FQ33564264-CC43B369-9146-4BCA-AAB5-99E1B6CAB6C8Q33680928-B8EB405F-874C-459D-A4B6-C9DB40F51DA4Q33688828-642115B6-04F2-41BE-BAC7-F9E92D75F446Q33689870-B6E989BB-4B66-438F-8FDF-8CE6ED893D1FQ33704489-AD11B1BB-B2D7-4988-B545-38A09F3CB9A9Q33747504-4AC9A3B1-A098-496D-954D-B31A69912F63Q33838733-5812C256-DD2B-46CA-8D9B-30BF60A86559Q33849195-FC2B38F7-8087-42C1-B93B-CB639A212345Q33930178-3EEBB83B-4513-4704-B32E-202FC28CB19FQ33939106-091FB527-70C1-428A-B87D-DA7FB49F1692Q33975484-87D1015D-5084-4AAB-9D02-0996FBEEE066Q33999606-0DD8DC64-27F6-486B-8B24-700FE61FC078Q34068822-A9FEC9C5-32E4-44B9-AAA5-644866DCFAEFQ34097241-6AD05216-4EC2-46C6-86D1-8615FE9BFFC6Q34132999-D07D86C1-CAB3-4A98-812F-1C3D20307ABFQ34138372-72EBA2CD-D31C-446C-BCA9-932984ED8391Q34139691-13275700-8857-427F-95C2-3B5C97393D20Q34277650-181178F7-F7F6-4D6E-9B5F-7E20E232E70AQ34428370-4FE8EFF2-D087-48A9-8A5C-0CDA49F84A59Q34474267-801ED776-B486-4D66-89F5-DBFB83A40EEBQ34561798-790FE6E7-F22A-477E-AEB5-0D935D6F99B6Q34564468-9E629221-41F8-492A-A84C-8D08FF3F6ECF
P2860
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
description
2003 nĆ® lÅ«n-bĆ»n
@nan
2003 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2003 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2003幓ć®č«ę
@ja
2003幓č«ę
@yue
2003幓č«ę
@zh-hant
2003幓č«ę
@zh-hk
2003幓č«ę
@zh-mo
2003幓č«ę
@zh-tw
2003幓č®ŗę
@wuu
name
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@ast
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@en
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@nl
type
label
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@ast
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@en
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@nl
prefLabel
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@ast
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@en
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@nl
P3181
P1476
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
@en
P2093
Avi Ashkenazi
P304
P3181
P356
10.1016/S1359-6101(03)00029-7
P407
P50
P577
2003-06-01T00:00:00Z